Sign In
Buy RXRX
$3.52
+0.180 (+5.39%)
At Close: Jun 26, 2026
Recursion to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 04'th Nov 2025
Salt Lake City, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in t
Cwm LLC Has $60,000 Stake in Recursion Pharmaceuticals, Inc. $RXRX
03:45am, Tuesday, 04'th Nov 2025
Cwm LLC cut its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) by 51.0% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned
Ethic Inc. Takes $107,000 Position in Recursion Pharmaceuticals, Inc. $RXRX
04:11am, Saturday, 01'st Nov 2025
Ethic Inc. purchased a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) in the undefined quarter, according to the company in its most recent filing with the SEC. The instituti
Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock?
06:15am, Friday, 31'st Oct 2025
Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet.
Top Biotech Stocks To Keep An Eye On – October 28th
02:15am, Thursday, 30'th Oct 2025
Danaher, argenex, Recursion Pharmaceuticals, Vertex Pharmaceuticals, and Medpace are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of
Earnings Preview: Recursion Pharmaceuticals (RXRX) Q3 Earnings Expected to Decline
11:07am, Wednesday, 29'th Oct 2025
Recursion Pharmaceuticals (RXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors
06:51pm, Tuesday, 28'th Oct 2025
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $5.91, indicating a -6.19% shift from the previous trading day.
Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th
08:00am, Tuesday, 28'th Oct 2025
Salt Lake City, UT, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide bu
Recursion Pharmaceuticals (RXRX) CEO Sells 100,000 Shares
12:07pm, Monday, 20'th Oct 2025
Christopher Gibson, Chief Executive Officer of Recursion Pharmaceuticals (RXRX 15.70%), reported the sale of 100,000 shares on October 10, 2025, as disclosed in a SEC Form 4 filing. It appears that Gi
3 Growth Stocks to Invest $1,000 in Right Now
04:00am, Sunday, 19'th Oct 2025
It's tough to get excited about buying most growth stocks right now. Too many of them are just too expensive relative to the risk they bring to the table.
Recursion Pharmaceuticals (RXRX) Suffers a Larger Drop Than the General Market: Key Insights
06:51pm, Thursday, 16'th Oct 2025
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $6.36, moving 6.33% from the previous trading session.
Is Recursion Pharmaceuticals a Millionaire Maker?
09:31am, Thursday, 16'th Oct 2025
Some investors closely monitor the portfolios of billionaires to get ideas. Another approach, however, is to examine the stocks held by highly successful companies.
4 Healthcare Stocks to Buy Now
09:45am, Sunday, 12'th Oct 2025
Healthcare stocks have struggled since interest rates began climbing in 2022. Rising yields pulled capital away from speculative biotech and drug development, pushing valuations lower even as research
What's Going On With Recursion Pharmaceuticals Stock On Wednesday?
02:51pm, Wednesday, 08'th Oct 2025
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement.
Recursion Pharmaceuticals (RXRX) Surges 8.2%: Is This an Indication of Further Gains?
10:56am, Friday, 03'rd Oct 2025
Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in
